CareLit · DOI-Nachweis · Geburtshilfe und Frauenheilkunde
Preclinical evaluation of the PARP-inhibitor olaparib for the treatment of ovarian clear cell cancer
DOI 10.1055/s-0031-1286501
Bibliografische Angaben
Nachweis in CareLit
Autor:innenKJ Dedes, P Wilkerson, D Wetterskog, MB Lambros, R Natrajan, D Tan, CJ Lord, SB Kaye, A Ashworth, JS Reis-Filho
ZeitschriftGeburtshilfe und Frauenheilkunde
Ausgabe08/2011
Jahrgang / SeitenNicht angegeben
Kernaussage aus der Literatur
Abstract-Vorschau
Fragestellung: Ovarian clear cell carcinoma (OCCC) is an aggressive histological subtype of epithelial ovarian cancer. De-novo resistance to platinum-based chemotherapy is higher compared to serous ovarian cancers. The aims of this study were to examine the role of a potent poly(ADP) ribose polymerase (PARP)-inhibitor as a potential therapeutic option for OCCCs and if RAD51 foci formation would constitute a surrogat…
Zitieren
Zitierempfehlung
KJ Dedes, P Wilkerson, D Wetterskog, MB Lambros, R Natrajan, D Tan, CJ Lord, SB Kaye, A Ashworth, JS Reis-Filho (2011) Preclinical evaluation of the PARP-inhibitor olaparib for the treatment of ovarian clear cell cancer. Geburtshilfe und Frauenheilkunde (08). https://doi.org/10.1055/s-0031-1286501
Mit CareLit weiterarbeiten